Garry Nolan - Akoya Biosciences Independent CoFounder
| AKYA Stock | USD 2.14 0.06 2.73% |
Insider
Garry Nolan is Independent CoFounder of Akoya Biosciences
| Age | 62 |
| Address | 100 Campus Drive, Marlborough, MA, United States, 01752 |
| Phone | 855 896 8401 |
| Web | https://www.akoyabio.com |
Akoya Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1809) % which means that it has lost $0.1809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.282) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, Akoya Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 59.4 M, whereas Total Assets are forecasted to decline to about 157.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Francis Tan | Haemonetics | N/A | |
| Warner H | The Cooper Companies, | 56 | |
| Brian Bonnell | ICU Medical | 50 | |
| Matthew DellaMaria | AptarGroup | N/A | |
| Deborah Yount | AtriCure | 58 | |
| Tonya SPHR | AtriCure | 50 | |
| Kimberly Chainey | AptarGroup | 48 | |
| Keisha Harcum | Milestone Scientific | N/A | |
| Mark Drury | The Cooper Companies, | 45 | |
| Carla Burigatto | Haemonetics | N/A | |
| B Owens | AptarGroup | 66 | |
| Jeannine Sheehan | InfuSystems Holdings | 48 | |
| A Bender | The Cooper Companies, | 79 | |
| Farris Maunsell | Haemonetics | 48 | |
| Teresa Madden | The Cooper Companies, | 65 | |
| Thomas Ruiz | InfuSystems Holdings | 66 | |
| Isabel MareySemper | AptarGroup | 53 | |
| Gerard III | The Cooper Companies, | 59 | |
| CCEP CCEP | AtriCure | 52 | |
| Angela CPA | AtriCure | 46 | |
| Juan Aragon | The Cooper Companies, | N/A | |
Management Performance
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.18 |
Akoya Biosciences Leadership Team
Elected by the shareholders, the Akoya Biosciences' board of directors comprises two types of representatives: Akoya Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akoya. The board's role is to monitor Akoya Biosciences' management team and ensure that shareholders' interests are well served. Akoya Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akoya Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Clifford Hoyt, VP Affairs | ||
| Brian McKelligon, CEO President | ||
| Marilee MBA, Chief Officer | ||
| Jennifer Kamocsay, General Counsel | ||
| Nikolay Samusik, CoFounder | ||
| Pascal Bamford, Research President | ||
| Priyam Shah, Senior Strategy | ||
| JD CFA, Secretary | ||
| Niro Ramachandran, Chief Officer | ||
| Yury Goltsev, CoFounder | ||
| Joseph Driscoll, Chief Officer | ||
| John Ek, Principal CFO | ||
| Garry Nolan, Independent CoFounder | ||
| Paul Grass, Senior Sales | ||
| Frederic Pla, Chief Officer |
Akoya Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akoya Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.65) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 155.09 M | ||||
| Shares Outstanding | 49.56 M | ||||
| Shares Owned By Insiders | 11.09 % | ||||
| Shares Owned By Institutions | 70.18 % | ||||
| Number Of Shares Shorted | 1.27 M | ||||
| Price To Book | 7.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.16) | Revenue Per Share 1.889 | Quarterly Revenue Growth (0.01) | Return On Assets (0.18) | Return On Equity (1.28) |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.